Clin Osteol 2005; 10(4): 75-79

New directions and findings in the concept of renal osteopathyReview articles

I. Sotorník, P. Bubeníček, C. Povýšil

The renal osteopathy (RO) is traditionally sorted by different stages of bone turnover: high turnover, represented by secondary hyperparathyroidism; and low bone turnover, characterized by osteomalatic syndrome and adynamic bone disease; intermediate forms can occur as well. The histomorphologic evaluation ofbone tissue remains the gold standard for diagnosis of RO. New aspects in the field of RO have the follwing implications: 1. The key factor of calcium and phosphate homeostasis and the pathogenesis of secondary hyperparathyroidism are the calcium sensing receptors localized at the surface of parathyroid and renal tubular cells. 2. The phosphate homeostasis is strongly influenced by the phosphaturic factors: phosphatonins. 3. The essential question in the RO diagnosis is the validity of parathyroid hormone (PTH) analysis. Currently used IRMA methods detecting intact PTH are burdened by various portion of PTH fragments, thus increasing the final results of the measurements. 4. From the pathogenetic point of view, very im­ portant role is played by the local factors and growth factors of bone metabolism. 5. As the patients on dialysis grow old, significant skeletal demine­ ralization can be anticipated. 6. 50 % of all deceased patients on dialysis die of in calcium-phosphate metabolism are likely to contribute to these causes of deaths.

Keywords: classification of renal ost

Published: December 11, 2005  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Sotorník I, Bubeníček P, Povýšil C. New directions and findings in the concept of renal osteopathy. Osteologický bulletin. 2005;10(4):75-79.
Download citation

References

  1. Schiavi SC, Kumar R. The phosphat homeostasis. Kidney Int 2004;65:1-4. Go to original source...
  2. Drueke TB. Modulation and actio Transplant 2004;19(Suppl 5):20-26. Go to original source...
  3. Llach F, Fernandez E. Overview of renal disease: Causes of treatment failure, nical observations, the changing pattern of bone lesions, and future therapeutic approach. Kidney Int 2003;64(Suppl 87):113-19. Go to original source...
  4. Elder G. Pathophysiology and recent advances in the management of renal osteo­ dystrophy. J Bone Miner Res 2002;17:2094-2105. Go to original source...
  5. Cueto-Manzano AM, Konel S, Freemont AJ, et al. Effect of 1,25-hydroxyvitamin D3 and calcium carbonate on bone loss associated with long-term renal trans­ plantation. Am J Kidney Dis 2000;35:227-36. Go to original source...
  6. Sperschneider H, Stein Transplant 2003;18:874-77.
  7. Schrooten I, Elseviers MM, Lamberts LV, et al. Increased serum strontium in dialysis patients: An epidemiological survey. Kidney Int 1999;56:1886-92. Go to original source...
  8. Sugimoto T, Ritter C, Morrissey J, et al. Effects of high concentrations of glu se on PTH secretion in parathyroid cells. Kidney Int 1990;37:1522-27 Go to original source...
  9. Kazama JJ, Maruyama H, Gejyo F. Osteoclastogenesis and osteoclast activation in dialysis - related amyloid osteopathy. Am J Kidney Dis 2001;38(Suppl 1):156-60. Go to original source...
  10. Ferreira MA Diagnosis of renal osteodystrophy: when and how to use biochemi­ cal markers and non-invasive methods; when bone-biopsy is needed. Nephrol Dial Transplant 2000;15(Suppl 5):8-14. Go to original source...
  11. DeBroe, D'Haese PC. Improving outcomes in hyperphosphataemia. Nephrol Dial Transplant 2004;19(Suppl 1):14-18. Go to original source...
  12. Gal-Moscovici A, Popovtzer MM. New worldwide trends in presenttion of renal osteodystrophy and its relationship to parathyroid hormone levels. Clin Nephrol 2005;63:284-89. Go to original source...
  13. Malluche HH, Monier-Faugere MC. Understanding and managing hyperphospha­ temia in patients with chronic renal disease. Clin Nephrol 1999;52:267-77.
  14. Brown EM, Gamba G, Riccardi D, et al. Cloning and characterization of an ex­ tracellular Ca2+-sensing receptor from bovine parathyroid. Nature 1993;366: 575-80. Go to original source...
  15. Quarles LD. Extracellular calcium-sensing receptors in the para ney, and other tissues. Curr Opin Nephrol Hypertens 2003;12:349-55. Go to original source...
  16. Canalejo A, Canadillas S, Ballesteros E, et al. Importance of arachidonic a mediator of parathyroid gland response. Kidney Int 2003;63(Suppl 85):10-13. Go to original source...
  17. Berson SA, Yalow RS. Immunoassay of bovine and human parathyroid hormone. Proc Nat Acad Sci (Wash) 1963;49:613-17 Go to original source...
  18. Sotorník I, et al. Kostní choroba při nezvratném selhání ledvin. 1st e Scientia medica, 1994:81-88.
  19. Malluche HH, Mawad H, Trueba D, Monier-Faugere MC. Parathyroid hormone assays - evolut 2003;59:313-18. Go to original source...
  20. Reichel H, Esser A, Roth H-J, Schmidt-Gayk H. Influence of PTH assay metho­ dology on diffe 2003;18:759-68.
  21. Urena P, de Vernejoul M-Ch. Circulating biochemical markers of bone remod ting in uremic patients. Kidney Int 1999;55:2141-56. Go to original source...
  22. Jehle PM, Jehle DR, Mohan S, Keller F. Renal osteodystrophy: New insights in pathophysiology and treatment modalities like growth factors. Nephron 1998;79:249-64. Go to original source...
  23. Hofbauer LC. Osteoprotegerin ligand and osteoprotegerin: novel implicati osteoclast biology and bone metabolism. Europ J Endocrinol 1999;141:195-210. Go to original source...
  24. Coen G, Ballanti P, Balducci A, et al. Serum osteoprotegerin and renal oste trophy. Nephrol Dial Transplant 2002;17:233-38. Go to original source...
  25. Cunningham J, Sprague SM. Osteoporosis in chronic kidney disease. Am J Kid­ ney Dis 2004;43:566-71. Go to original source...
  26. Sotorník I, Bubeníček P, Karasová L, et al. Sekundární hyperparat le aktuální problém chronických nefropatií. Osteol Bul 2003;8:115-18.
  27. Block GA, Port FK. Re-evaluation of risk associated with hyperphosphatemia hyperparathyroidism in dialysis patients:: Recommendations for a change in ma­ nagement. Am J Kidney Dis 2000;35:1226-37. Go to original source...
  28. Gamesh SK, Stack AG, Levin NW, et al. Association of elevated serum PO(4), Ca x PO(4) product and parathyroid hormone with cardiac mortality risk in chro­ nic hemodialysis patients. J Am Soc Nephrol 2001;12:2131-38. Go to original source...
  29. Shioi A, Taniwaki H, Jono S, et al. Monckeberg_s medial phosphate in uremia. Am J Kidney Dis 2001;38(Suppl 1):47-49. Go to original source...
  30. Floege J, Ketteler M. Vascular calcification in pa sease. Nephrol Dial Transplant 2004;19(Suppl 5):59-66. Go to original source...
  31. Kaden JJ, Bickelhaupt S, Grobholz R. Receptor activator of nuclear osteoprotegerin regulate aortic valve calcification. J Mol Coll Cardiol 2004;36:57-66. Go to original source...
  32. Ketteler M, Gross M-L, Ritz E: Calcification and cardiovascular problems in nal failure. Kidney Int 2005;94(Suppl 94):120-27. Go to original source...
  33. Virchow R. Cellular pathology: as based upon physiological and pathological histology. New York: Dover, 1863; nezkrácený reprint 1971:404-08. Go to original source...




Clinical Osteology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.